Risk factors
Grace Therapeutics (GRCE) risk factors
Item 1A of every Grace Therapeutics, Inc. 10-K on file, and what changed from one year to the next.
- FY2026 10-K risk factors
52 risks, 6 new, 1 dropped, 10 reworded since the prior year. FDA’s April 2026 CRL for GTx-104 now dominates risks, with manufacturing deficiencies potentially delaying or preventing approval.
Filed Jun 18, 2026 - FY2025 10-K risk factors
47 risks. The risk section is dominated by heavy dependence on the lead drug candidate GTx-104, ongoing operating losses, and regulatory hurdles.
Filed Jun 23, 2025